153 related articles for article (PubMed ID: 16850327)
21. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
22. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
[TBL] [Abstract][Full Text] [Related]
23. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
Dammann HG; Burkhardt F; Wolf N
Aliment Pharmacol Ther; 1999 Sep; 13(9):1195-203. PubMed ID: 10468701
[TBL] [Abstract][Full Text] [Related]
24. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
[TBL] [Abstract][Full Text] [Related]
25. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of intravenous esomeprazole at 2 different dosages in dogs.
Seo DH; Lee JB; Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2019 Mar; 33(2):531-535. PubMed ID: 30548689
[TBL] [Abstract][Full Text] [Related]
29. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
Ohning GV; Barbuti RC; Kovacs TO; Sytnik B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 2000 Jun; 14(6):701-8. PubMed ID: 10848652
[TBL] [Abstract][Full Text] [Related]
30. Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.
Röhss K; Wilder-Smith C; Nauclér E; Jansson L
Clin Drug Investig; 2004; 24(1):1-7. PubMed ID: 17516685
[TBL] [Abstract][Full Text] [Related]
31. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Miner P; Delemos B; Xiang J; Lococo J; Ieni J
Aliment Pharmacol Ther; 2010 May; 31(9):991-1000. PubMed ID: 20132153
[TBL] [Abstract][Full Text] [Related]
32. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
[TBL] [Abstract][Full Text] [Related]
33. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
Armstrong D; James C; Camacho F; Chen Y; Horbay GL; Teixeira B; Husein-Bhabha FA
Aliment Pharmacol Ther; 2007 Jan; 25(2):185-96. PubMed ID: 17116123
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.
Hwang JH; Jeong JW; Song GH; Koo TS; Seo KW
J Vet Intern Med; 2017 May; 31(3):743-750. PubMed ID: 28407418
[TBL] [Abstract][Full Text] [Related]
35. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
36. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
37. Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients : a randomized, double-blind, placebo-controlled study.
Gursoy O; Memiş D; Sut N
Clin Drug Investig; 2008; 28(12):777-82. PubMed ID: 18991471
[TBL] [Abstract][Full Text] [Related]
38. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
39. Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
Armstrong D; Bair D; James C; Tanser L; Escobedo S; Nevin K
Aliment Pharmacol Ther; 2003 Oct; 18(7):705-11. PubMed ID: 14510744
[TBL] [Abstract][Full Text] [Related]
40. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.
Pisegna JR; Sostek MB; Monyak JT; Miner PB
Aliment Pharmacol Ther; 2008 Mar; 27(6):483-90. PubMed ID: 18162083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
